{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-303393","form_type":"8-K","ticker":"RNA","cik":"0002093101","company_name":"Atrium Therapeutics, Inc.","filed_at":"2026-07-14T21:14:28+00:00","discovered_at":"2026-07-14T21:16:00.287060+00:00","generated_at":"2026-07-14T21:16:06.911443+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atrium Therapeutics receives FDA IND clearance for ATR 1072 in PRKAG2 syndrome; Phase 1/2 trial to start","bullets":["FDA cleared IND for ATR 1072, a precision cardiology RNA therapeutic for PRKAG2 syndrome.","Corventis Phase 1/2 trial will enroll ~37 participants; first patient expected by end of 2026.","Initial proof-of-concept data anticipated in second half of 2027.","PRKAG2 syndrome is a rare genetic cardiomyopathy with no approved therapy addressing root cause.","This is Atrium's first precision cardiology program to enter clinic."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-303393","json":"https://secwatch.observer/filing/0001193125-26-303393.json","markdown":"https://secwatch.observer/filing/0001193125-26-303393.md","text":"https://secwatch.observer/filing/0001193125-26-303393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526303393/0001193125-26-303393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526303393/d132402d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T21:16:06.911443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}